All In Biotech

NDA 017284 · Shine

Xenon Xe 133

Xenon Xe-133 · Inhalation · Inhalation Diagnostic Agent

Last checked: Nov 19, 2026Latest source record: Jun 10, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1974

Oct 10, 1974

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4

3 Phase 3, 1 recruiting

FAERS reports

13

2 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 10, 2026.

INDICATIONS AND USAGE: Inhalation of Xenon Xe 133 Gas has proved valuable for the evaluation of pulmonary function and for imaging the lungs. It may also be applied to assessment of cerebral flow.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 10, 1974 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • XENON XE 133 · XENON XE-133 10mCi/VIAL · GAS, INHALATION · Prescription
  • XENON XE 133 · XENON XE-133 20mCi/VIAL · GAS, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Xenon Xe-133" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • occupational exposure to product4
  • nasal discomfort2
  • throat irritation2
  • urticaria2
  • accidental exposure1
  • accidental exposure to product1
  • alanine aminotransferase decreased1
  • beta 2 microglobulin increased1
  • blood alkaline phosphatase increased1
  • blood bilirubin decreased1
  • blood cholinesterase decreased1
  • blood creatine phosphokinase decreased1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
20162
20182
20192
20201
20245

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Shine

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.